ASX Announcements

13 December 2021

Compensation options

LCT will now issue 147,480,853 Options pro rata to eligible participants in the Company’s Placement of Shares and Notes announced on 19 October 2021. This is the maximum number that may be issued by the Company under Listing Rule 7.1, and no Options may be issued under Listing Rule 7.1A.

An additional 22,678,567 Options will be issued ...

13 December 2021

Proposed issue of securities

Proposed issue of options expiring 19 April 2024.

13 December 2021

Cleansing notice

Living Cell Technologies Limited (ASX: LCT) announces the issue of options by way of placement to sophisticated and wholesale investors by the issue of:

1. 30,753,181 placement options, and

2. 116,727,672 options (on conversion of convertible notes)

All Options are being issued with an exercise price of $0.015 with an exp...

13 December 2021

Dr Belinda Di Bartolo Appointed COO

Dr Belinda Di Bartolo has been appointed as Chief Operating Officer. Dr Di Bartolo will lead the planning and preparations for the third clinical trial of NTCELL in Parkinson’s disease.

Dr Di Bartolo has 18 years’ experience in health and medical research. She has a clear understanding of the translational pathway of researc...

9 December 2021

Update to proposed issue of securities

Update of key dates as a result of the extension of the closing date.